Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Emactuzumab - Roche

Drug Profile

Emactuzumab - Roche

Alternative Names: RG-7155; RO-5509554

Latest Information Update: 11 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Roche; SynOx Therapeutics; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Macrophage colony stimulating factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pigmented villonodular synovitis; Giant cell tumour of tendon sheath
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Giant cell tumour of tendon sheath
  • Phase II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
  • Discontinued Pigmented villonodular synovitis

Most Recent Events

  • 05 Jan 2023 Argonaut Therapeutics has merged with Celleron Therapeutics to form IngenOx Therapeutics
  • 31 Aug 2022 Preliminary efficacy and adverse events data from a phase I/II trial in Giant cell tumour of tendon sheath released by SynOx Therapeutics
  • 31 Aug 2022 Emactuzumab - Roche receives Orphan Drug status for Giant cell tumour of tendon sheath in European Union
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top